



**Company Contacts:
Nuvectra Corporation**

Walter Berger, COO & CFO
(214) 474-3102
wberger@nuvectramed.com

Jennifer Armstrong, Media Relations
(214) 474-3110
jarmstrong@nuvectramed.com

**Investor Contacts:
The Ruth Group**

Zack Kubow
(646) 536-7020
zkubow@theruthgroup.com

Brian Johnston
(646) 536-7028
bjohnston@theruthgroup.com

Nuvectra to Participate in Morgan Stanley Global Healthcare Conference

Plano, Texas, August 30, 2017 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & CFO, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York, NY.

Event: Morgan Stanley Global Healthcare Conference

Date: Monday, September 11, 2017

The Company will be participating in one-on-one investor meetings at the conference and will not make a formal presentation. If interested in meeting with management, please reach out to Brian Johnston at bjohnston@theruthgroup.com, or your Morgan Stanley contact.

About Nuvectra Corporation

Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson's Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.